Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer

Annual Review of Physiology

Volumn 69, Issue , 2007, Pages 171-199

  Lange, Carol A ^a   Gioeli, Daniel ^a   Hammes, Stephen R ^b   Marker, Paul C ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Androgen receptor; Cyclin D1; Epidermal growth factor; Mitogen activated protein kinase; Progesterone receptor

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE RECEPTOR; PROTEIN P300; RAF PROTEIN; RAS PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; WNT1 PROTEIN;

BREAST CANCER; FEMALE; GENE EXPRESSION REGULATION; GROWTH REGULATION; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION;

ANDROGENS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; SIGNAL TRANSDUCTION;

EID: 33947401482     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.69.031905.160319     Document Type: Review

References (156)

1. Condon JC, Hardy DB, Kovaric K, Mendelson CR. 2006. Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-κB may contribute to the onset of labor through inhibition of PR function. Mol. Endocrinol. 20:764-75
2. Pratt VVB, Toft DO. 2003. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 228:111-33
3. Moore MR, Zhou JL, Blankenship KA, Strohl JS, Edwards DP, Gentry RN. 1997. A sequence in the 5′ flanking region confers progestin responsiveness on the human c-myc gene. J. Steroid Biochem. Mol. Biol. 62:243-52
4. Chalbos D, Chambon M, Ailhaud G, Rochefort H. 1987. Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J. Biol. Chem. 262:9923-26
5. Krusekopf S, Chauchereau A, Milgrom E, Henderson D, Cato AC. 1991. Co-operation of progestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells. J. Steroid Biochem. Mol. Biol. 40:239-45
6. Dehm SM, Tindall DJ. 2006. Molecular regulation of androgen action in prostate cancer. J. Cell Biochem. 99:333-34
7. Lange CA, Richer J K, Shen T, Horwitz KB. 1998. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J. Biol. Chem. 273:31308-16
8. Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB. 1995. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res. 55:3197-203
9. Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, et al. 2005. Induction of AP-I activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. Prostate 63:155-68
10. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz, KB. 1998. Convergence or progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J. Biol. Chem. 273:31317-26
11. Gregory CW, Johnson RTJ, Presnell SC, Mohler JL, French FS. 2001. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J. Androl. 22:537-48
12. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, et al. 1997. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27 (Kip1). Mol. Endocrinol. 11:1593-607
13. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB. 1998. Progesterone regulates transcription of the p21 (WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem. 273:10696-701
14. Tseng L, Tang M, Wang Z, Mazella J. 2003. Progesterone receptor (hPR) upregulates the fibronectin promoter activity in human decidual fibroblasts. DNA Cell Biol. 22:633-40
15. Proietti C, Salatino M, Rosemblit C, Carnevale R, Pecci A, et al. 2005. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol. Cell Biol. 25:4826-40
16. McKenna NJ, O'Malley BW. 2002. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465-74
17. Smith LD, Ecker RE. 1969. Role of the oocyte nucleus in physiological maturation in Rana pipiens. Dev. Biol. 19:281-309
18. Masui Y. 2001. From oocyte maturation to the in vitro cell cycle: the history of discoveries of Maturation-Promoting Factor (MPF) and Cytostatic Factor (CSF). Differentiation 69:1-17
19. Hammes SR. 2004. Steroids and oocyte maturation - a new look at an old story. Mol. Endocrinol. 18:769-75
20. Lutz LB, Cole LM, Gupta MK, Kwist KW, Auchus RJ, Hammes SR. 2001. Evidence that androgens are the primary steroids produced by Xenopus laevis ovaries and may signal through the classical androgen receptor to promote oocyte maturation. Proc. Natl. Acad. Sci. USA 98:13728-33
21. White SN, Jamnongjit M, Gill A, Lutz LB, Hammes SR. 2005. Specific modulation of nongenomic androgen signaling in the ovary. Steroids 70:352-60
22. Jamnongjit M, Hammes SR. 2005. Oocyte maturation: the coming of age of a germ cell. Semin. Reprod. Med. 23:234-41
23. Staack A, Kassis AP, Olshen A, Wang Y, Wu D, et al. 2003. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 54:212-19
24. Denis LJ, Griffiths K. 2000. Endocrine treatment in prostate cancer. Semin. Surg. Oncol. 18:52-74
25. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. 1995. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 55:3068-72
26. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10:33-39
27. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61:3550-55
28. Edwards J, Bartlett JM. 2005. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int. 95:1320-26
29. Edwards J, Bartlett JM. 2005. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int. 95:1327-35
30. Gioeli D. 2005. Signal transduction in prostate cancer progression. Clin. Sci. 108:293-308
31. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, et al. 1994. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54:2577-81
32. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LW. 1992. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J. Urol. 147:1151-59
33. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. 1993. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53:1102-6
34. Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5:280-85
35. Mellinghoff IK, Tran C, Sawyers CL. 2002. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. 62:5254-59
36. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, et al. 2002. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:121-37
37. McIlinghoff IK, Vivancol, Kwon A, Tran C, Wongvipat J, Sawyers CL. 2004. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517-27
38. Carter BS, Epstein JI, Isaacs WB. 1990. ras gene mutations in human prostate cancer. Cancer Res. 50:6830-32
39. Voeller HJ, Wilding G, Gelmann EP. 1991. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol. Endocrinol. 5:209-16
40. Bakin RE, Giocli D, Sikes RA, Bissonette EA, Weber MJ. 2003. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63:1981-89
41. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, et al. 2000. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44:91-103
42. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. 2003. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res. 63:1975-80
43. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, Luttrell LM. 1999. Activation of extracellular signal-regulated kinase in human prostate cancer. J. Urol. 162:1537-42
44. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. 2002. Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum. Pathol. 33:299-306
45. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, et al. 2002. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem. 277:29304-14
46. Zhu Z, Becklin RR, Desiderio DM, Dalton JT. 2001. Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry. Biochem. Biophys. Res. Commun. 284:836-44
47. Zhou ZX, Kemppainen JA, Wilson EM. 1995. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol. Endocrinol. 9:605-15
48. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. 1999. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 96:5458-63
49. Lin HK, Yeh S, Kang HY, Chang C. 2001. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. USA 98:7200-5
50. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, et al. 2000. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60:6841-45
51. Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, et al. 2006. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol. Endocrinol. 20:503-15
52. Taneja SS, Ha S, Swenson NK, Huang HY, Lee P, et al. 2005. Cell-specific regulation of androgen receptor phosphorylation in vivo. J. Biol. Chem. 280:40916-24
53. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, et al. 2003. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J. Biol. Chem. 278:50902-7
54. Itoh M, Adachi M, Yasui H, Takekawa M, Tanaka H, Imai K. 2002. Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol. Endocrinol. 16:2382-92
55. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA. 2003. Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol. Endocrinol. 17:628-42
56. Lee H, Bai W. 2002. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell Biol. 22:5835-45
57. Rowan BG, Weigel NL, O'Malley BW. 2000. Phosphorylation of steroid receptor coactivator-I. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 275:4475-83
58. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, et al. 2004. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem. 279:7119-30
59. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW. 1998, Partial hormone resistance in mice with disruption ofthe steroid receptor coactivator-1 (SRC-I) gene. Science 279:1922-25
60. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, et al. 2001. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61:4315-19
61. Heinlein CA, Chang C. 2002. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23:175-200
62. Yeh S, Kang HY, Miyamoto H, Nishimura K, Chang HC, et al. 1999. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine 11:195-202
63. Debes JD, Schmidt LJ, Huang H, Tindall DJ. 2002. P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res. 62:5632-36
64. Huang H, Tindall DJ. 2002. The role of the androgen receptor in prostate cancer. Crit. Rev. Enkaryot. Gene Expr. 12:193-207
65. Nusse R. 2003. Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface. Development 130:5297-305
66. Pandur P, Maurus D, Kuhl M. 2002. Increasingly complex: New players enter the Wnt signaling network. Bioessays 24:881-84
67. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, et al. 2002. Linking beta-catenin to androgen-signaling pathway. J. Biol. Chem. 277:11336-44
68. Truica CI, Byers S, Gelmann EP. 2000. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 60:4709-13
69. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. 2002. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J. Biol Chem. 277:17933-43
70. Verras M, Brown J, Li X, Nusse R, Sun Z. 2004. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res. 64:8860-66
71. Massague J. 1990. The transforming growth factor-beta family. Annu. Rev. Cell Biol. 6:597-641
72. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, et al. 1996. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531-42
73. Massague J. 1998. TGF-β signal transduction. Annu. Rev. Biochem. 67:753-91
74. Zhu B, Kyprianou N. 2005. Transforming growth factor β and prostate cancer. Cancer Treat. Res. 126:157-73
75. Hayes SA, Zarnegar M, Sharma M, Yang F, Pcehl DM, et al. 2001. SMAD3 represses androgen receptor-mediated transcription. Cancer Res. 61:2112-18
76. van der Poel HG. 2005. Androgen receptor and TGFβ1/Smad signaling are mutually inhibitory in prostate cancer. Eur. Urol. 48:1051-58
77. Kang HY, Lin HK, Hu YC, Yeh S, Huang KF, Chang C. 2001. From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc. Natl. Acad. Sci. USA 98:3018-23
78. Kang HY, Huang KF, Chang SY, Ma WL, Lin WJ, Chang C. 2002. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J. Biol. Chem. 277:43749-56
79. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, et al. 2002. The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3. J. Biol. Chem. 277:1240-48
80. Hovey RC, Trott JF, Vonderhaar BK. 2002. Establishing a framework for the functional mammary gland: from endocrinology to morphology. J. Mammary Gland Biol. Neoplasia 7:17-38
81. Haslam SZ, Counterman LJ, Nummy KA. 1993. Effects of epidermal growth factor, estrogen, and progestin on DNA synthesis in mammary cells in vivo are determined by the developmental state of the gland. J. Cell Physiol. 155:72-78
82. Ankrapp DP, Bennett JM, Haslam SZ. 1998. Role of epidermal growth factor in the acquisition of ovarian steroid hormone responsiveness in the normal mouse mammary gland. J. Cell Physiol. 174:251-60
83. Robinson GW, Hennighausen L, Johnson PF. 2000. Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev. 14:889-94
84. Li Y, Rosen JM. 2005. Stem/progenitor cells in mouse mammary gland development and breast cancer. J. Mammary Gland Biol. Neoplasia 10:17-24
85. Aupperlee MD, Smith KT, Kariagina A, Haslam SZ. 2005. Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology 146:3577-88
86. Chlebowski RT, Hendrix SL, Longer RD, Stefanick ML, Gass M, et al. 2003. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243-53
87. Haslam SZ, Osuch JR, Raafat AM, Hofseth LJ. 2002. Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model. J. Mammary Gland Biol. Neoplasia 7:93-105
88. Booth BW, Smith GH. 2006. Estrogen receptor-α and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands. Breast Cancer Res. 8:R49
89. Clarke RB. 2006. Ovarian steroids and the human breast: regulation of stem cells and cell proliferation. Maturitas 54: 327-34
90. Dunn KL, Espino PS, Drobic B, He S, Davie JR. 2005. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem. Cell Biol. 83:1-14
91. Shen Q, Brown PH. 2003. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J. Mammary Gland Biol. Neoplasia 8:45-73
92. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, et al. 2005. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother. Pharmacol. 56(Suppl. 1):10-20
93. Lange CA. 2004. Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: Who will have the last word? Mol. Endocrinol. 18:269-78
94. Zhang Y, Beck CA, Poletti A, Clement JP, Prendergast P, et al. 1997. Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol. Endocrinol. 11:823-32
95. Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL. 1995. Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol. Endocrinol. 9:1029-40
96. Takimoto GS, Tasser DM, Eppert AC, and Horwitz KB. 1992. Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc-finger mutants and the progesterone antagonist ZK89299. Proc. Natl. Acad. Sci. USA 89:3050-54
97. Sartorius CA, Takimoto GS, Richer JK, Tung L, Horwitz KB. 2000. Association of the Ku autoantigen/DNA-dependent protein kinase holoenzyme and poly(ADP-ribose) polymerase with the DNA binding-domain of progesterone receptors. J. Mol. Endocrinol. 24:165-82
98. Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL. 1994. Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J. Biol. Chem. 269:31034-40
99. Lange CA, Shen T, Horwitz KB. 2000. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl. Acad. Sci. USA 97:1032-37
100. Shen T, Horwitz KB, Lange CA. 2001. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol. Cell Biol. 21:6122-31
101. Knotts TA, Orkiszewski RS, Cook RG, Edwards DP, Weigel NL. 2001. Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J. Biol. Chem. 276:8475-83
102. Font de Mora J, Broun M. 2000. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell Biol. 20:5041-47
103. Narayanan R, Adigun AA, Edwards DP, Weigel NL. 2005. Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyelin A/Cdk2 as a progesterone receptor coactivator. Mol. Cell Biol. 25:264-77
104. Labriola L, Salatino M, Proietti CJ, Pecci A, Coso OA, et al. 2003. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol. Cell Biol. 23:1095-111
105. Pierson-Mullany LK, Lange CA. 2004. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol. Cell Biol. 24:10542-57
106. Takimoto CIS, Hovland AR, Tasset DM, Melville MY, Tung L, Horwitz KB. 1996. Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors. J. Biol. Chem. 271:13308-16
107. Simons SSJ. 2006. How much is enough? Modulation of dose-response curve for steroid receptor-regulated gene expression by changing concentrations of transcription factor. Curr Top Med. Chem. 6:271-85
108. Qiu M, Lange CA. 2003. MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J. Steroid Biochem. Mol. Biol. 85:147-57
109. Migliaccio A, Di Domenico M, Green S, de Falco A, Kajtaniak EL, et al. 1989. Phosphorylation on tyrosine of in vitro synthesized human estrogen receptor activates its hormone binding. Mol. Endocrinol. 3:1061-69
110. Ali S, Metzger D, Bornert JM, Chambon P. 1993. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J. 12:1150-60
111. Narayanan R, Edwards DP, Weigel NL. 2005. Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol. Cell Biol. 25:2885-98
112. Nardulli AM, Katzenellenbogen BS. 1988. Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. Endocrinology 122:1532-40
113. Sheridan PL, Krett NL, Gordon JA, Horwitz KB. 1988. Human progesterone receptor transformation and nuclear down-regulation are independent of phosphorylation. Mol. Endo. 2:1329-42
114. Musgrove EA, Swarbrick A, Lee CS, Cornish AL, Sutherland RL. 1998. Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell Biol. 18:1812-25
115. Edwards DP, Weigel NL, Nordeen SK, Beck CA. 1993. Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. Breast Cancer Res. Treat. 27:41-56
116. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. 2002. Phosphorylation- dependent ubiquitinylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 21:4037-48
117. Muratani M, Tansey WP. 2003. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell Biol. 4:192-201
118. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. 2000. The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol. Cell 5:939-48
119. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, et al. 1996. Tyrosine kinase/p21 tras/MAP-kinase pathway activation by estradiol-receptor complex in MCE-7 cells. EMBO J. 15:1292-300
120. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, et al. 1998. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17:2008-18
121. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, et al. 2001. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell8:269-80
122. Migliaccio A, Castoria G, Di Domenico M, de Faleo A, Bilancio A, et al. 2000. Steroid-induced androgen receptor-estradiol receptor p-Src complex triggers prostate cancel-cell proliferation. EMBO J. 19:5406-17
123. Migliaccio A, Castoria G, Di Domenico M, Beato C, Beato M, Auricchio F. 2005. The progesterone receptor/estradiol receptor association and the progestin-triggered S-phase entry. Ernst Schering Res. Found. Workshop 52:39-54
124. Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, et al. 2003. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Frk pathway in mammalian cells. Mol. Cell Biol. 23:1994-2008
125. Wong C, McNally C, Nickbarg E, Komm B, Cheskis B. 2002. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc. Natl. Acad. Sci. USA 99:14783-88
126. Haas D, White SN, Lutz LB, Rasar M, Hammes SR. 2005. The modulator of nongenomic actions ofthe estrogen receptor (MNAR) regulates transcription- independent androgen receptor-mediated signaling: evidence that MNAR participates in G protein-regulated meiosis in Xenopus laevis oocytes. Mol. Endocrinol. 19:2035-46
127. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, et al. 2004. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 64:7156-68
128. Zhoul J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT. 2005. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res. 65:9906-13
129. Zhu Y, Bond J, Thomas P. 2003. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc. Natl. Acad. Sci. USA 100:2237-42
130. Skildum A, Faivre E, Lange CA. 2005. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol. Endocrinol. 19:327-39
131. Murphy LO, Blenis J. 2006. MAPK signal specificity: the right place at the right time. Trends Biochem. Sci. 31:268-75
132. Santen R, Jeng MH, Wang JP, Song R, Masamura S, et al. 2001. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J. Steroid Biochem. Mol. Biol. 79:115-25
133. Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, et al. 2006. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch. 449:24-30
134. Doane AS, Danso M, Lal P, Donaton M, Zhang L, et al. 2006. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25:3994-4008
135. 1-arrested human breast cancer cells. Oncogene 12:2315-24
136. Knudsen KE, Arden KC, Cavenee WK. 1998. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J. Biol. Chem. 273:20213-22
137. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, et al. 1994. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54:1812-17
138. Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, et al. 2000. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab. Invest. 80:1455-64
139. Knudsen KE, Cavenee WK, Arden KC. 1999. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res. 59:2297-301
140. Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, et al. 2006. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc. Natl. Acad. Sci. USA 103:2190-95
141. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, et al. 2005. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122:33-43
142. Carroll JS, Brown M. 2006. Estrogen receptor target gene: an evolving concept. Mol. Endocrinol. 20:1707-14
143. Marino M, Acconcia F, Bresciani F, Weisz A, Trentalance A. 2002. Distinct nongenomic signal transduction pathways controlled by 17β-estradiol regulate DNA synthesis and cyclin D, gene transcription in HepG2 cells. Mol. Biol. Cell 13:3720-29
144. Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP. 2000. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol. Endocrinol. 14:52-65
145. Albanese C, Johnson J, Watanabe C, Eklund N, Vu D, et al. 1995. Transforming p21 ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 270:23589-97
146. Reed SI. 1997. Control of the G1/S transition. Cancer Surv. 29:7-23
147. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-77
148. Lukas J, Bartkova J, Bartek J. 1996. Convergence of mitogenic signaling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol. Cell Biol. 16:6917-25
149. Cheng M, Sexl V, Sherr CJ, Roussel MF. 1998. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. USA 95:1091-96
150. Kolar Z, Murray PG, Scott K, Harrison A, Vojtesek B, Dusek J. 2000. Relation of Bcl-2 expression to androgen receptor, p21WF1/C1P1, and cyclin D1 status in prostate cancer. Mol. Pathol. 53:15-18
151. Agus DB, Cordon-Cardo CC, Fox W, Drobnjak M, Koff A, et al. 1999. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer lust. 91:1869-76
152. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. 1995. Mice lacking cyclin D1 are small and show defects in eve and mammary gland development. Genes Dev. 9:2364-72
153. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, et al. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-30
154. Lydon JP, DeMayo FJ, Conneely OM, O'Malley BW. 1996. Reproductive phenotpes of the progesterone receptor null mutant mouse. J. Steroid. Biochem. Mol. Biol. 56:67-77
155. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, et al. 2003. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114:323-34
156. Seagroves TN, Krnacik S, Raught B, Gay J, Burgess-Beusse B, et al. 1998. C/EBPβ, but not C/EBPα, is essential tor ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev. 12:1917-28